ArticleHaematologica2013

The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.

Thoralf Lange et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.